Gynecologic Cancer News

The addition of atezolizumab to bevacizumab and first-line chemotherapy improved PFS and OS compared with standard chemotherapy alone among women with metastatic, persistent or recurrent cervical cancer, study results showed.

HPV detectability was associated with better clinical cervical cancer prognosis vs. no detectable virus with up to a 41% lower mortality risk, according to a systematic review and meta-analysis published in Obstetrics & Gynecology.

A regimen containing dostarlimab plus standard-of-care chemotherapy significantly improved OS compared with chemotherapy alone in women with primary advanced or recurrent endometrial cancer, according to the agent’s manufacturer.

A virtual mind-body fitness program reduced unplanned hospitalizations, number of hospitalization days and urgent care visits among patients undergoing active cancer treatment, study results showed.

MADRID — Induction chemotherapy prior to chemoradiation therapy improved outcomes for women with locally advanced cervical cancer, according to randomized phase 3 study results presented at ESMO Congress.

The National Academy of Medicine announced the election of 90 regular members and 10 international members.

ASCO released a research statement outlining new recommendations regarding the appropriate assessment of ovarian toxicity in cancer clinical trials.

Women with abnormal Pap or HPV test results who did not undergo colposcopy within 12 months had higher risk for subsequent cervical cancer compared with women who received colposcopy within that time frame, researchers reported.

The FDA announced several regulatory actions.

PHILADELPHIA — Current ovarian cancer screening methods are ineffective, but women can reduce their risk for ovarian cancer with opportunistic salpingectomy — removing the fallopian tubes at time of other surgeries, according to a presenter.